Implantable cardioverter-defibrillators for children and young adolescents: mortality benefit confirmed—what’s next?

S F Sears, J B Conti

The implantable cardioverter-defibrillator can present significant psychological difficulties for some younger patients, not least because of increased lifestyle disruption and the likely experience of shock.

The implantable cardioverter-defibrillator (ICD) is the treatment of choice for potentially life-threatening ventricular arrhythmias. Consistent with the adult clinical trial data for both primary and secondary prevention, Gradaus and colleagues' followed children and young adolescents with ICDs for an average of four years and found that the children's total survival was excellent (95.8%). The demonstrated mortality benefit demonstrated by Gradaus and colleagues in this issue of Heart allows us to turn our attention to psychosocial issues and quality of life (QoL) of young ICD patients.

We reported that younger age and greater frequency of ICD firings were the two most commonly reported ICD specific risk factors for psychological distress. Younger patients (50 years and younger) may experience greater problems because of increased lifestyle disruption and distressing social comparisons. In addition to adjusting to the risk of potentially life-threatening arrhythmias, young patients must deal with the presence of the ICD device, the likely experience of life saving shock, and the social and lifestyle ramifications of the ICD. Not surprisingly, the ICD can present significant psychological difficulties for some young patients.

In adults, the occurrence of ICD specific fears and symptoms of anxiety (for example, excessive worry, physiological arousal) are the most common psychological symptoms experienced by ICD recipients, with approximately 13–38% of recipients experiencing diagnosable levels of anxiety. Depressive symptoms are reported at rates that are generally consistent with other cardiac populations (24–33%). A national US sample of healthcare providers estimated that 10–20% of their ICD patients experience reductions in QoL, emotional wellbeing, and family relationships. We would expect to see the same magnitude of distress, if not greater, in children.

QUALITY OF LIFE IMPACT

ICD shock is clearly the primary culprit when patients describe a decrease in quality of life, and coping with both inappropriate and appropriate shocks remains the most significant psychosocial challenge for ICD populations. Schron and colleagues concluded that the experience of at least one ICD shock was associated with reduced mental wellbeing and physical functioning. Irvine and associates demonstrated that five or more shocks was the threshold for a decreased quality of life outcome. Although ICD shocks feel the same whether they are appropriate or inappropriate, coping with inappropriate shocks is particularly difficult and may be associated with increased distress and potential distrust of the accuracy and effectiveness of the ICD. The potential differential response of patients to inappropriate versus appropriate shocks underscores the importance of psychological factors in the adjustment to the ICD.

The success described by Gradaus and colleagues is tempered by the percentage of inappropriate shocks (38%) that children appeared to encounter. Although inappropriate treatment in adult ICD patients has dramatically fallen over the last several years, inappropriate therapy in children remains a problem. Data from Chechin and colleagues indicated that approximately 24% of children with ICDs eventually encounter lead fracture associated with physical growth, an obvious precursor to inappropriate shock. Taken together with other recent paediatric reports, the available studies suggest that the ICD for young children and young adults provides mortality benefit, but children may experience a disproportionate number of lead problems and inappropriate shocks. Although this should not prevent implantation of devices in those patients in whom they are clearly life saving, these data should be considered by the physician, patient, and families involved before implantation, particularly for primary prevention.

ICD TREATMENT VERSUS ANTIARRHYTHMIC MEDICATION

QoL research in adults shows that ICD treatment is at least equal to or better than antiarrhythmic medications on patient reported and objective indicators of QoL. For example, a large randomised controlled trial (Canadian Implantable Defibrillator Antiarrhythmic mantle versus ICDs) indicated that QoL was significantly better for ICD patients in all spheres, except for pain and social functioning. Unfortunately, data regarding QoL in young ICD patients does not exist.

Based on the information available, routine psychological care for all ICD patients is
reasonable,14 and young ICD patients are a subgroup well suited for this care. Specifically, patient adjustment and peer acceptance of the ICD are key developmental milestones for the young ICD patient. Descriptive and prospective research designs are still needed to address the substantial psychosocial changes and specific lifestyle and activity recommendations for young patients with ICDs. Restriction of normal activity may be particularly heinous in the young patient. Although to do no harm is the first medical objective, prohibition of desired physical activity is also problematic. In summary, we need data describing how young ICD patients perform when they do return to normal life. Returning to a full life is the hallmark feature of quality of life. Comprehensive, interdisciplinary care plans, such as those reported by Fitchet and colleagues,15 demonstrate that an exercise and stress management programme is a safe and valuable addition for ICD patients and results in reduced anxiety and improved exercise capacity. The current study by Gradaus and colleagues’ confirms mortality benefits, which, if coupled with increased attention to QoL, will ultimately provide ideal health outcomes for young ICD patients.

Authors’ affiliations
S F Sears, Department of Clinical Health Psychology, University of Florida, Gainesville, Florida, USA
J B Conti, Division of Cardiovascular Medicine, University of Florida

REFERENCES

IMAGES IN CARDIOLOGY

Acute incomplete thrombotic occlusion of distal left main coronary artery treated by tissue plasminogen activator

A 76 year old man presented with chest pain; he had a personal history of hypertension, diabetes mellitus, and pneumoconiosis. He was hospitalised because of an inferior myocardial infarction. On the fifth day of his clinical follow up in the coronary intensive care unit, the patient experienced chest discomfort and palpitation, and an ECG revealed atrial fibrillation and ST segment depression. Afterwards, coronary angiographic examination revealed a thrombus that was narrowing the lumen to 80% at the bifurcation of the left anterior descending coronary artery (LAD) and the left circumflex coronary artery (LCx) distal to the left main coronary artery (panel A). TIMI II flow was present at the distal LAD and LCx. The patient was treated with tissue plasminogen activator (tPA) because of intra coronary thrombus. One hour after the onset of treatment, the angina pectoris ceased and a normal sinus rhythm returned. ST segment depressions and T wave inversions on anterior derivatives returned to normal. Cardiac troponin I concentration increased to 2 ng/dl (normal limits 0.01–0.1 ng/dl). The patient was diagnosed with non-ST elevation myocardial infarction. Coronary angiography was repeated two days later. The large thrombus in the distal left main coronary artery was found to have resolved (panel B).

Several pathogenic processes, besides atherosclerosis, are known to involve the coronary arteries and to be responsible for severe acute coronary syndromes. Coronary embolism is included among non-atherosclerotic entities causing acute myocardial infarction and should be suspected in the presence of atrial fibrillation, and left atrial or ventricular thrombus. We report a case of distal left main coronary artery thrombus which was detected by coronary angiography and treated by tissue plasminogen activator.
Implantable cardioverter-defibrillators for children and young adolescents: mortality benefit confirmed—what's next?
S F Sears and J B Conti

Heart 2004 90: 241-242
doi: 10.1136/hrt.2003.021295

References
This article cites 10 articles, 4 of which you can access for free at:
http://heart.bmj.com/content/90/3/241#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Drugs: cardiovascular system (8842)
Epidemiology (3752)
Interventional cardiology (2933)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/